|Articles|September 1, 2001
NB-UVB yields encouraging responses in early stage MF patients
Treatment compares favorably with PUVA, thanks, in part, to better long-term safety profile
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.